Lexicon Pharmaceuticals
LXRX
123 hedge funds and large institutions have $243M invested in Lexicon Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 31 increasing their positions, 36 reducing their positions, and 33 closing their positions.
455% more call options, than puts
Call options by funds: $805K | Put options by funds: $145K
98% more capital invested
Capital invested by funds: $122M → $243M (+$120M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2.96% less ownership
Funds ownership: 73.52% → 70.57% (-3%)
3% less funds holding
Funds holding: 127 → 123 (-4)
12% less first-time investments, than exits
New positions opened: 29 | Existing positions closed: 33
14% less repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 36
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.33M |
| 2 |
SC
Sessa Capital
New York
|
+$1.94M |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$1.31M |
| 4 |
Millennium Management
New York
|
+$1.06M |
| 5 |
Jane Street
New York
|
+$521K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$4.31M |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
-$2.36M |
| 3 |
State Street
Boston,
Massachusetts
|
-$1.16M |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$1.1M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$850K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
151
US Bancorp
Minneapolis,
Minnesota
| – | -$499 | -1,082 | Closed |
|
|
PS
152
Pinney & Scofield
Cambridge,
Massachusetts
| – | -$461 | -1,000 | Closed |
|
153
Citadel Advisors
Miami,
Florida
| – | -$263 | -406 | Closed |
|
|
SIC
154
SJS Investment Consulting
Sylvania,
Ohio
| – | -$185 | -400 | Closed |
|
|
NA
155
NewEdge Advisors
New Orleans,
Louisiana
| – | -$2 | -5 | Closed |
|
LXRX Hedge Fund Activity: Q2 2025 in Review
123 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Lexicon Pharmaceuticals (LXRX) for Q2 2025, worth a combined $243M — up 98% from $122M a quarter earlier.
Sellers outnumbered buyers: 33 funds closed out of LXRX and 29 opened new positions — a net loss of 4 holders — while 36 trimmed existing stakes and 31 added.
The largest buyer was Fidelity Investments, adding an estimated $2.33M. The largest seller was BlackRock, cutting an estimated $4.31M.
- 123 institutional investors held Lexicon Pharmaceuticals (LXRX) as of Q2 2025, down from 127 in Q1 2025.
- Funds reported $243M of Lexicon Pharmaceuticals stock for Q2 2025, up 98% quarter-over-quarter.
- 29 funds opened new Lexicon Pharmaceuticals positions in Q2 2025 and 33 closed out, a net change of -4 holders.
- The largest Lexicon Pharmaceuticals buyer in Q2 2025 was Fidelity Investments, an estimated $2.33M added.
- The largest Lexicon Pharmaceuticals seller in Q2 2025 was BlackRock, an estimated $4.31M sold.
Based on aggregated 13F filings for Q2 2025.